Introduction {#Sec1}
============

Despite the moderate absolute risk of a bisphosphonate user to suffer an atypical fracture \[[@CR1]\], the patient and physician's fear of atypical fractures seems to have contributed to a recent decline in prescription rates for antiresorptives \[[@CR2]\]. The common notion that atypical fractures are associated with a high risk of perioperative complications and a higher risk of delayed healing or non-union as well as consequential reoperations might have reinforced those fears \[[@CR3]--[@CR8]\]. The perception of a poor healing capacity is based on case reports \[[@CR9], [@CR10]\] and case series \[[@CR5], [@CR6], [@CR11]--[@CR13]\], which contrast results from animal and human studies showing no negative impact of bisphosphonates on fracture healing, except for callus remodeling \[[@CR14], [@CR15]\]. In long-term bisphosphonate exposure, the severe suppression of bone turnover has been suggested to decrease the anabolic response of the skeleton leading to impaired fracture healing \[[@CR6]\]. However, because the local healing capacity in the cortical bone of patients treated with surgical resection of an incomplete AFF (stress fracture that has not yet broken completely) appears normal \[[@CR16]\], impairment of fracture healing is even less likely for the healing of complete AFFs \[[@CR17]\]. Case studies reporting an increased risk of healing complications might have been distorted by other factors (e.g., patient background characteristics, drug treatment \[[@CR18]\], and death \[[@CR19]\]) rather than the atypical fracture itself and associated bisphosphonate treatment.

Radiographic evaluation of fracture healing is inconsistent, especially in a retrospective study design \[[@CR20]\]. Reoperations, on the other hand, can be objectively recorded. Our primary aim was to test the hypothesis that the proposed increased risk of reoperation and specifically the increased risk for reoperations related to complicated fracture healing will disappear in a time-to-event analysis after consideration of differences in patient background characteristics. A secondary aim was to analyze the effect modification of use or non-use of bisphosphonates before and after an atypical fracture on the rate of reoperation.

Materials and methods {#Sec2}
=====================

Study population {#Sec3}
----------------

In this nationwide cohort study comprising patients with either complete atypical or common low-energy subtrochanteric and femoral shaft fractures, we recorded all reoperations after the initial fracture. Reoperations related to healing complications were identified and used as a proxy variable for delayed or non-healing.

All patients ≥ 55 years who were treated as inpatients for a fractured femur between 2008 and 2010 were identified through the Swedish National Inpatient Register (Fig. [1](#Fig1){ref-type="fig"}). We only included patients if the fracture was located in the subtrochanteric or diaphyseal region as defined by ICD-10 codes (International Classification of Diseases, 10th Revision \[ICD-10\]) in the register (diagnosis code S722 or S723) and only fractures associated with low-energy trauma (external cause code W \[i.e., excluding any type of transportation accident\]). In cases of bilateral fractures, only the first was included to avoid selection bias.Fig. 1Patient selection and identification of reoperations based on individual radiographic review and data from national registers (from 1 January 2008 to 31 December 2014). SCB: Statistics Sweden. Mechanically altered femur: preexisting implants, underlying bone conditions altering skeletal biomechanics (i.e. previous fractures, Paget´s disease of the bone, tumours, etc.)

This patient cohort has been investigated previously \[[@CR1]\] and includes 5475 patients in a nationwide population of 2,891,586 women and men in Sweden. Of these 5475 patients, 4351 omitted because the location or nature of the fracture excluded an atypical fracture or rendered the fracture inappropriate for comparison with atypical fractures. The majority of these patients had pertrochanteric femur fractures erroneously coded as subtrochanteric femur fractures and implants in the ipsilateral femur. The original cohort that served as the source for this investigation included 1124 patients (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR1], [@CR21]\].

Fracture types {#Sec4}
--------------

Atypical fractures were classified based on radiographic criteria of the revised version of the American Society of Bone and Mineral Research (ASBMR) task force criteria \[[@CR3]\]. A transverse fracture line originating from the lateral side and focal cortical thickening at the fracture site were compulsory criteria \[[@CR1], [@CR3], [@CR17], [@CR22]\]. Fractures were registered as either subtrochanteric (tip of the lesser trochanter and 5 cm distal to it) or diaphyseal (to the supracondylar flare) \[[@CR23]\]. Common fractures (CFFs) were defined as spiral, oblique, or comminute fractures \[[@CR3]\]. Only complete fractures were included. Both reviewers (GZ, HPB) were blinded to all background information. The final classification into fracture types was based on the previous classification \[[@CR1]\].

Identification of reoperations {#Sec5}
------------------------------

We used two complementary approaches to identify reoperations.

First, we retrieved all radiographic images (including magnetic resonance) of the affected femur from all radiology departments throughout Sweden (*n* = 76) between the date of the initial fracture and 31 December 2014. All images were screened for any changes in the morphology of the bone, the fracture and fixation devices indicating that a reoperation might had been performed. Among all reoperations, we identified those related to a complicated course of healing (Table [3](#Tab3){ref-type="table"}) where at least one of the following radiographic signs was present: incomplete obliteration of the fracture line, incomplete cortical continuity, or implant failure. In patients who had undergone multiple reoperations, only the most complex reoperation was used in the statistical analyses to reflect the most relevant clinical impact for the patient. Dynamization procedures were not considered as reoperations due to healing complications because there is no high-quality evidence to support dynamization as a means to improve fracture healing \[[@CR24]--[@CR26]\]. The time interval between the initial fracture and the main reoperation was calculated in days. We excluded 99 patients from the original cohort of 1124 patients because of incomplete radiographic imaging (*n* = 51), preexistent implants (*n* = 39), or other reasons (*n* = 9).

In a second step, we retrieved data from the Swedish National Patient Register (NPR) on every admission for each individual patient from the initial fracture admission until 31 December 2014. We only considered admissions with the discharge diagnosis S72, T84, T81, T93, M84, M80.9, and M96, combined with a surgical procedure code of the Swedish version of the NOMESCO classification of surgical procedures (Supplementary Table [1](#MOESM1){ref-type="media"}). The comparison with register data yielded another 13 reoperations (AFF = 3, CFF = 10). These reoperations included 10 screw removals, one arthroscopy, one reoperation due to hemorrhage, and one unspecified reoperation. The final study cohort included 1025 patients (AFF *=* 163; CFF = 862).

Registers {#Sec6}
---------

In Sweden, all permanent residents are provided a unique personal identification number that allows complete linkage with all nationwide registers. Data on drug use were obtained from the Swedish Prescribed Drug Register \[[@CR1], [@CR21]\], including data on dispensing of bisphosphonates and oral corticosteroids before and after the fracture admission \[[@CR19]\]. Drug treatment was defined as ever use. Discharge diagnoses were collected from the NPR from 1987 and for outpatient visits from 2001 until 31 December 2014 \[[@CR1], [@CR21]\]. Depending on type, the positive predictive value of diagnoses registered in the NPR ranges from 85 to 100% \[[@CR27]\]. All diagnoses before the date of the fracture were included to calculate the individual weighted Charlson's comorbidity index at baseline \[[@CR28]\].

We determined dates of death after fracture events by linkage to the National Population Register of the Swedish Tax Agency. Calculated from the period of inclusion (years 2008 through 2010), the mortality rate was determined for up to 7 years (until 31 December 2014) after the fracture event. The study was approved by the regional ethical review board in Linköping, (DNR 2014/407-31, 2015/382-32).

Statistical analysis {#Sec7}
--------------------

The risk of reoperation was calculated for each fracture type. Furthermore, age-adjusted odds ratios (ORs, using unconditional logistic regression) and relative risks (RRs, using log-binomial regression) were calculated separately for any type of reoperation and those related to healing complications. Odds ratios and relative risks were then further adjusted for the following predefined variables: sex, Charlson's comorbidity index, and corticosteroid treatment. In addition to risk assessments, we performed time-to-event analysis using Cox regression to estimate age and multivariable-adjusted cause-specific hazard ratios (csHRs) for any type of reoperation and those related to healing complications. Age-standardized incidence rates were calculated, by use of direct standardization and five-year age intervals, with the age distribution of CFF patients as a reference.

We used the group of patients with CFF as a control group because they were representative of the general population of patients with underlying vulnerability to fractures and refrained from matching to avoid the introduction of selection bias \[[@CR29]\].

We performed competing risk analysis (as a sensitivity analysis) with death as the competing event due to known differences in mortality rate \[[@CR19]\].

We additionally used stratified analyses to estimate the impact of use and non-use of bisphosphonates on the hazard for reoperation. Stratified multivariable-adjusted csHRs were calculated and are presented as a forest plot (Fig. [2](#Fig2){ref-type="fig"}). Stata (version 15) and IBM SPSS (version 25) were used for statistical analyses.Fig. 2Stratified, multivariable-adjusted cause-specific hazard ratios (*x*-axis) for any reoperation

Results {#Sec8}
=======

Patient and implant characteristics are listed in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}.Table 1Patient background characteristicsAFFCFFN163862Age, mean (SD)76.6 (8.19)82.2 (9.58)SexMale11 (6.7%)169 (19.6%)Female152 (93.3%)693 (80.4%)Charlson´s comorbidity index, median (IQR)3 (1--5)3 (1--6)Time to complication (years)^1^, median (IQR)0.74 (0.46--1.2)0.64 (0.19--1.3)OutcomeNo event104 (63.8%)290 (33.6%)Reoperation28 (17.2%)74 (8.6%)Death31 (19.0%)498 (57.8%)Time to death (years)^2^, median (IQR)2.8 (1.9--4.2)1.9 (0.4--3.4)Follow-up time (years), median (IQR)4.5 (2.7--5.5)3.2 (0.9--4.9)Bisphosphonate use before the fracture127 (77.9%)102 (11.8%)Bisphosphonate use after the fracture (first year)110 (67.5%)127 (14.7%)Bisphosphonate use before fracture. Duration (years), mean (SD)3.64 (1.1)2.34 (1.65)Corticosteroid use49 (30.1%)140 (16.2%)Fracture locationSubtrochanteric25 (15.3%)559 (64.8%)Diaphyseal138 (84.7%)303 (35.2%)^1^For those with complication; ^2^For those who died during observation intervalTable 2Frequencies of implants usedImplantAFFCFFTotal*N*%*N*%N%AFN13884.761671.575473.6RFN2213.512114.014314.0Plate\*31.812514.512812.5Total1631008621001025100AFN antegrade femoral nail, RFN retrograde femoral nail\*any type of plate construct

Reoperations {#Sec9}
------------

Any type of reoperation was performed in 28 (17%) patients with AFFs and in 73 (8%) with CFFs (Table [3](#Tab3){ref-type="table"}). Reoperations related to healing complications were done in 9 patients with AFFs and in 23 with CFFs. Multiple reoperations were performed in 20 patients (8 AFF, and 12 CFF). The age-adjusted RR was 1.61 (95% CI, 1.07 to 2.43) for any reoperation and 1.69 (95% CI, 0.78 to 3.68) for reoperations related to healing complications. When further corrected for differences in the predefined variables (i.e., sex, Charlson's comorbidity index, corticosteroid treatment), the RRs were attenuated to 1.41 (95% CI, 0.92 to 2.17) for any reoperation and to 1.41 (95% CI, 0.63 to 3.17) for reoperations related to healing complications.Table 3Frequencies and types of reoperationsType of reoperationAFF (*N* = 163)CFF (*N* = 862)Reoperations related to healing complicationRevision from intramedullary nail to plate18Revision from plate to intramedullary nail15Intramedullary nail exchange77Hip arthroplasty in presence of non-union03Other reoperationsPartial implant removal212Complete implant removal25Dynamization procedure63Peri-implant fractures821Hip arthroplasty due to osteoarthritis02Other17Total2873

Adjusting for differences in follow-up time and accordingly unequal death rates (19% vs. 58% in patients with common fractures), the multivariable-adjusted csHR for any reoperation was 1.34 (95% CI, 0.85 to 2.13). A similar HR, though with lower precision, was calculated for reoperations related to healing complications as outcome. Expectedly, the subdistribution HRs for a reoperation were quite similar to the relative risk estimates (Table [4](#Tab4){ref-type="table"}).Table 4Differences in reoperation rates between atypical femoral fractures and common fractures of the femoral shaft based on different statistical methods. Odds ratios (ORs) calculated with binominal logistic regression. Cause-specific hazard ratios (csHRs) taking differences in follow-up time into account, using Cox regression. Subdistribution hazard ratios (sdHRs) using the fine and gray proportional subdistribution hazard regression (sdHR) model to control for differences in death rates between the groups. All with 95% confidence intervals (95% CI)**Event as binaryFracture typeNo. events(*N*)RiskAge-adjusted** OR (95% CI)**Multivariable-adjusted**\*  **OR (95% CI)Age-adjusted** **RR (95% CI)Multivariable-adjusted**\* **RR (95% CI)** ReoperationNFF748.6%Ref.Ref.Ref.Ref.AFF2817.2%1.76 (1.08--2.86)1.54 (0.93--2.56)1.61 (1.07--2.43)1.41 (0.92--2.17) Reoperation -healing complicationNFF232.7%Ref.Ref.Ref.Ref.AFF95.5%1.73 (0.76--3.92)1.46 (0.62--3.41)1.69 (0.78--3.68)1.41 (0.63--3.17)**Time to eventTime at risk(years)Age-standardized rate** **(events per 1000 person-year)Age-adjusted** **csHR (95% CI)Multivariable-adjusted**\*  **csHR (95% CI)Age-adjusted** **sdHR (95% CI)Multivariable-adjusted**\* **sdHR(95% CI)** ReoperationNFF265727.9Ref.Ref.Ref.Ref.AFF66935.01.49 (0.95--2.33)1.34 (0.85--2.13)1.69 (1.09--2.64)1.49 (0.92--2.42) Reoperation -healing complicationNFF28268.1Ref.Ref.Ref.Ref.AFF74015.01.55 (0.7--3.42)1.32 (0.58--3.0)1.71 (0.76--3.85)1.43 (0.57--3.58)\*Adjusted by age (continuous), sex, cortisone use (yes/no), and Charlson's comorbidity index (continuous)

Of the 163 patients with atypical fracture, 127 (78%) had received bisphosphonate treatment before the index fracture. Of the bisphosphonate users, 17 (13%) were reoperated for any reason; of the bisphosphonate non-users, 11 (31%) were reoperated for any reason: multivariable-adjusted csHR 0.34 (95% CI, 0.14 to 0.81). The rate remained lower even when reoperations related to healing complications were compared: multivariable-adjusted csHR 0.13 (95% CI, 0.03 to 0.54).

In contrast to patients with atypical fractures, bisphosphonate users who had had a common fracture displayed an increase in the rate of reoperations related to healing complications, with a multivariable-adjusted csHR of 2.62 (95% CI, 1.03 to 6.68). The multivariable-adjusted csHR for any type of reoperation was 1.65 (95% CI, 0.92 to 2.98). Continued use of bisphosphonate in the first year after the index fracture was not associated with an increased risk of any type of reoperation, regardless of fracture type.

Discussion {#Sec10}
==========

Consistent with our hypothesis, age-adjusted estimates showed an increased risk of reoperation in patients with atypical femoral fractures. This risk difference became substantially attenuated when predefined patient background characteristics and follow-up time were controlled.

Impaired fracture healing is one of the proposed clinical hallmarks of AFFs and was adopted as a minor criterion in the first ASBMR task force report \[[@CR3]\]. Numerous case reports have described increased reoperation rates after an atypical fracture\[[@CR5], [@CR10], [@CR30]--[@CR33]\], in one study as high as 46% \[[@CR11]\]. The criterion of delayed healing mainly referred to incomplete AFFs (stress fractures), with inhibition of direct bone healing (inhibition of targeted remodeling) suggested as a possible mechanism. This seems reasonable, because bisphosphonate treatment in animal models has shown accumulation of microdamage formation \[[@CR34]\] and inhibited resorption of fracture surfaces in stress fractures \[[@CR35]\]. Inhibited resorption was coupled with impairment of new bone formation thus leading to delayed fracture healing \[[@CR34], [@CR35]\]. However, when incomplete atypical fractures are excised by use of a full-thickness cortical bone biopsy, the cortical defect that remains heals by indirect fracture healing and the formation of new bone occurs at normal speed, despite long-term bisphosphonate treatment \[[@CR16]\]. This is not surprising because in indirect fracture healing, with the formation of an external callus, bone formation is uncoupled from bone resorption. This type of fracture healing therefore is typically not affected by bisphosphonates \[[@CR15]\]. The remodeling of the external callus on the other hand is delayed by bisphosphonates, because it involves osteoclast-derived resorption of callus tissue followed by lamellar bone formation through osteoblasts. Complete atypical fractures heal through the mechanism of indirect fracture healing, which supports our hypothesis that healing of complete atypical fractures should not be affected by bisphosphonate treatment.

In more recent reports, rates of reoperation in AFFs are much lower, especially with the use of cephalomedullary nails \[[@CR7], [@CR8], [@CR13], [@CR36], [@CR37]\]. Nonetheless, these recent reports describe a delayed union when using historic controls or the use of the conventional 6 months as the cut-off point for delayed healing \[[@CR8], [@CR38]\]. One study found an increased risk of complicated healing in AFF patients compared with controls, even when delayed healing was based not only on radiographic but also clinical signs \[[@CR39]\]. Risk estimates in that study, however, were not corrected for differences in patient background characteristics. The inability to correct for differences in patient background characteristics is a potential shortcoming in previous reports comparing outcomes of AFFs with other fracture types. In our study, we were not able to directly evaluate differences in fracture healing and instead used reoperations associated with complicated fracture healing as an indirect measure. The use of this proxy might introduce selection bias because the true number of patients with complicated healing remains unknown and might differ between groups. Given the retrospective design, we were not able to validate this proxy or directly control for it. However, in contrast to previous reports, we were able to control for multiple confounding factors and survival time, by using adjusted risk and time-to-event analyses with correction of predefined variables. With these adjustments, differences in reoperation rates associated with complicated healing were modest.

For a number of reasons, reoperation rates could conceivably differ between the two fracture groups. Patients with atypical fractures might expose the implant to greater stress during the period of fracture healing because of their younger age and more active lifestyle \[[@CR7], [@CR40]\]. This selection might be an effect of drug channeling bias as a consequence of treating younger and healthier patients with bisphosphonates \[[@CR41]\]. On the contrary, elderly patients with common fractures might not seek health care for a non-union or might be deemed unfit to undergo surgery. Such an effect is conceivable considering that more than half of the patients with common fractures died during the 4--7-year follow-up.

We observed a lower risk of reoperations in patients with atypical fractures treated with bisphosphonates compared with those without treatment, even in the multivariable-adjusted model. Little is known about this subgroup of patients expressing radiologic features of atypical fractures but without reported use of bisphosphonate. One possible explanation could be that patients without a history of bisphosphonate treatment suffer from undetected bone metabolic conditions with a predisposition for stress fractures and impaired fracture healing. Further investigations are needed to elucidate these differences. Continuation of bisphosphonate therapy during the first year after the fracture did not influence the risk of reoperation comparing atypical fractures with common fractures. These findings are in line with previous results \[[@CR7]\]. A shorter treatment duration before the fracture has been suggested to decrease the risk of complicated healing \[[@CR38], [@CR39], [@CR42]\]. However, sample sizes were small in those studies \[[@CR38]\].

A main strength of our study is the nationwide coverage and complete linkage between high-quality registers and radiographic adjudication of fracture site and features in accordance with current ASBMR criteria and our rigorous identification of reoperations, using two complementary methods. Limitations include the observational study design and the potential for residual confounding or undetected selection mechanisms related to fragility not captured by our study design. Differences in such factors between the two fracture types would probably result in further attenuation of our estimates. Because the majority of the patients in our cohort are of Caucasian origin, our results should be extrapolated to other ethnic groups with some reservation, especially given that atypical fractures are coupled to ethnicity and biomechanical aspects of femoral geometry \[[@CR43], [@CR44]\]. Patients in both groups were treated with different surgical techniques and implants. It is possible that some implants might be more beneficial depending on the fracture configuration. Such comparisons were beyond the scope of this study. Despite a relatively large number of patients in our cohort, the proportion of patients with complications was about 10%, resulting in a moderate precision of our estimates.

The results of our study confirm an increased risk of reoperation for patients with atypical fractures. However, it appears that patient-related factors such as health status and survival have a stronger impact on the reoperation risk than the type of fracture.
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